Outlook Therapeutics, Inc.
OTLK
$0.50
-$0.01-1.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -106.10% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -106.10% | -- | |||
| Cost of Revenue | -8.97% | -- | |||
| Gross Profit | -15.12% | -- | |||
| SG&A Expenses | 6.69% | 21.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.18% | 39.24% | |||
| Operating Income | -9.94% | -27.09% | |||
| Income Before Tax | 26.32% | 56.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.04% | 56.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.04% | 56.53% | |||
| EBIT | -9.94% | -27.09% | |||
| EBITDA | -9.96% | -27.15% | |||
| EPS Basic | 48.34% | 63.68% | |||
| Normalized Basic EPS | 36.25% | 67.83% | |||
| EPS Diluted | 48.53% | 63.37% | |||
| Normalized Diluted EPS | 36.25% | 67.83% | |||
| Average Basic Shares Outstanding | 27.70% | 19.70% | |||
| Average Diluted Shares Outstanding | 27.70% | 19.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||